a possible trendgold
Over the 4 study years, we noted a possible trend of decreasing utilization of ICI monotherapy, which could be attributable to decreased patient numbers in 2020 or secondary to an increase at our academic center in ICI-based clinical trial options that enrolled immunotherapy-naïve patients, who were thus excluded from this observational study.